1. International Conference on Harmonisation. (2006).Impurities in New Drug Substances. Q3A(R2). Revised Guideline.
2. International Conference on Harmonisation. (2006).Impurities in New Drug Products. Q3B(R2). Revised Guideline.
3. International Conference on Harmonisation. (2017).Assessment and Control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk. M7. Revised guideline (R1).